As Dicerna Pharmaceuticals (DRNA) Stock Rose, Holder Longwood Capital Partners Raised Its …

… with their article: “Tracking Seth Klarman’s Baupost Group Holdings – Q2 2019 Update – Seeking Alpha” published on August 16, 2019, Finance.

Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) Logo

Longwood Capital Partners Llc increased its stake in Dicerna Pharmaceuticals Inc (DRNA) by 16.93% based on its latest 2019Q2 regulatory filing with the SEC. Longwood Capital Partners Llc bought 55,675 shares as the company’s stock rose 8.52% . The institutional investor held 384,500 shares of the health care company at the end of 2019Q2, valued at $6.06M, up from 328,825 at the end of the previous reported quarter. Longwood Capital Partners Llc who had been investing in Dicerna Pharmaceuticals Inc for a number of months, seems to be bullish on the $998.74M market cap company. The stock decreased 1.68% or $0.25 during the last trading session, reaching $14.61. About 249,568 shares traded. Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) has risen 9.57% since September 14, 2018 and is uptrending. It has outperformed by 9.57% the S&P500. Some Historical DRNA News: 08/03/2018 – DICERNA PHARMACEUTICALS – BELIEVES IT HAS SUFFICIENT CASH TO FUND EXECUTION OF CURRENT CLINICAL AND OPERATING PLAN THROUGH 2019; 17/04/2018 – STAT Plus: Trade secrets battle between Alnylam, Dicerna is just one of many; 09/04/2018 – Dicerna Presenting at Conference Tomorrow; 20/04/2018 – Biotech companies Alnylam, Dicerna settle trade secrets case; 20/04/2018 – DICERNA PHARMACEUTICALS INC – ALNYLAM WILL DISMISS ALL CLAIMS OF “TRADE SECRET MISAPPROPRIATION” & OTHER RELATED CLAIMS BROUGHT IN COURT AGAINST CO; 20/04/2018 – ALNYLAM REACHES SETTLEMENT PACT WITH DICERNA PHARMACEUTICALS; 08/03/2018 – DICERNA SEES SUFFICIENT CASH TO FUND DEVELOPMENT THRU 2019; 20/04/2018 – DICERNA PHARMACEUTICALS – ALNYLAM WILL DISMISS ALL CLAIMS OF “TRADE SECRET MISAPPROPRIATION” & OTHER RELATED CLAIMS BROUGHT IN COURT AGAINST CO; 19/04/2018 – DJ Dicerna Pharmaceuticals Inc, Inst Holders, 1Q 2018 (DRNA); 30/05/2018 – Dicerna Doses First Primary Hyperoxaluria Patient with DCR-PHXC in Group B Portion of PHYOX Phase 1 Clinical Trial

Manor Road Capital Partners Llc increased its stake in Liberty Global Plc (Call) (LBTYK) by 75.68% based on its latest 2019Q2 regulatory filing with the SEC. Manor Road Capital Partners Llc bought 1.40M shares as the company’s stock rose 0.89% . The hedge fund held 3.25 million shares of the television services company at the end of 2019Q2, valued at $86.22M, up from 1.85M at the end of the previous reported quarter. Manor Road Capital Partners Llc who had been investing in Liberty Global Plc (Call) for a number of months, seems to be bullish on the $20.16 billion market cap company. The stock increased 0.33% or $0.09 during the last trading session, reaching $27.51. About 4.41 million shares traded or 1.30% up from the average. Liberty Global Plc (NASDAQ:LBTYK) has declined 0.99% since September 14, 2018 and is downtrending. It has underperformed by 0.99% the S&P500. Some Historical LBTYK News: 09/05/2018 – Vodafone Group to Buy Liberty Assets in Germany, Hungary, Romania, Czech Republic; 30/05/2018 – European Commission Conditionally Approves Liberty Global’s Ziggo Buy; 23/05/2018 – Vodafone Is Said to Offer Bonds to Finance Liberty Global Deal; 23/04/2018 – Telecom Paper: Vodafone close to buying Liberty Global assets in Germany, East Europe – report; 09/05/2018 – ♫ Reuters Insider – U.S. Morning Call: Iran deal fallout; Liberty Global and Monster Beverage loses its fizz; 09/05/2018 – VODAFONE GROUP PLC VOD.L – TRANSACTION IS NOT SUBJECT TO VODAFONE OR LIBERTY GLOBAL SHAREHOLDER APPROVALS; 09/05/2018 – Vodafone challenges Deutsche Telekom with $21.8 bln Liberty deal; 09/05/2018 – Vodafone to pay $21.8 bln for Liberty assets to boost European presence; 23/03/2018 – LIBERTY GLOBAL PLC – AGREEMENT TO ACQUIRE MULTIMEDIA POLSKA S.A. HAS BEEN TERMINATED – SEC FILING; 08/05/2018 – Vodafone nears €18bn game-changing Liberty Global deal

More notable recent Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) news were published by: Nasdaq.com which released: “After-Hours Earnings Report for March 11, 2019 : ADT, COUP, SFIX, DRNA, AVD, PETQ, CCXI, LXFR, MG, OXFD, FRTA, KALA – Nasdaq” on March 11, 2019, also Finance.Yahoo.com with their article: “Here’s What Hedge Funds Think About Dicerna Pharmaceuticals Inc (DRNA) – Yahoo Finance” published on June 11, 2019, Seekingalpha.com published: “Dicerna Pharmaceuticals (DRNA) Presents At Cowen And Company 39th Annual Health Care Conference – Slideshow – Seeking Alpha” on March 12, 2019. More interesting news about Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) were released by: Seekingalpha.com and their article: “Dicerna prices follow-on common stock offering – Seeking Alpha” published on September 07, 2018 as well as Seekingalpha.com‘s news article titled: “Dicerna Pharmaceuticals (DRNA) To Present At SVB Leerink 8th Global Healthcare Conference – Slideshow – Seeking Alpha” with publication date: March 01, 2019.

Investors sentiment decreased to 1.52 in 2019 Q2. Its down 0.07, from 1.59 in 2019Q1. It is negative, as 10 investors sold DRNA shares while 21 reduced holdings. 19 funds opened positions while 28 raised stakes. 45.15 million shares or 2.31% less from 46.22 million shares in 2019Q1 were reported. Fosun Int Limited invested in 188,673 shares. 63,923 are owned by Rafferty Asset Limited Liability. Fmr Ltd Limited Liability Company invested in 0% or 667,948 shares. Northern Corporation stated it has 683,682 shares. Natl Bank Of Montreal Can, Ontario – Canada-based fund reported 4,298 shares. Legal General Grp Inc Pcl reported 0% of its portfolio in Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA). Td Asset Mngmt has 53,480 shares. Ny State Common Retirement Fund has invested 0% in Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA). Acuta Partners Limited Liability holds 384,500 shares or 2.15% of its portfolio. Birchview Limited Partnership reported 0.43% of its portfolio in Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA). Dafna Capital Ltd Liability reported 118,314 shares. Ra Cap Mgmt Lc holds 2.08% or 2.46 million shares in its portfolio. Blackrock holds 4.27 million shares. Voya Mngmt Ltd Liability reported 22,263 shares. 25,673 are owned by Proshare Limited Com.

Since May 29, 2019, it had 0 buys, and 1 sale for $20.00 million activity.

More notable recent Liberty Global Plc (NASDAQ:LBTYK) news were published by: Streetinsider.com which released: “Liberty Global (LBTYA) Announces Preliminary Results of Modified Dutch Auction Tender Offers – StreetInsider.com” on September 10, 2019, also Seekingalpha.com with their article: “Tracking Seth Klarman’s Baupost Group Holdings – Q2 2019 Update – Seeking Alpha” published on August 16, 2019, Finance.Yahoo.com published: “Seth Klarman’s Baupost Boosts Liberty, Reduces eBay – Yahoo Finance” on August 15, 2019. More interesting news about Liberty Global Plc (NASDAQ:LBTYK) were released by: Nasdaq.com and their article: “Vanguard FTSE All-World ex-US ETF Experiences Big Inflow – Nasdaq” published on August 20, 2019 as well as Finance.Yahoo.com‘s news article titled: “Liberty Global PLC (LBTYK) Q2 2019 Earnings Call Transcript – Yahoo Finance” with publication date: August 09, 2019.

Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) Institutional Positions Chart

Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.

Related Posts:

  • No Related Posts

Two Sigma Investments LP Acquires 34433 Shares of Dicerna Pharmaceuticals Inc (DRNA)

Two Sigma Investments LP raised its holdings in Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) by 42.1% in the fourth quarter, Holdings Channel …

Dicerna Pharmaceuticals logoTwo Sigma Investments LP raised its holdings in Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) by 42.1% in the fourth quarter, Holdings Channel reports. The fund owned 116,152 shares of the biopharmaceutical company’s stock after buying an additional 34,433 shares during the period. Two Sigma Investments LP’s holdings in Dicerna Pharmaceuticals were worth $1,242,000 at the end of the most recent reporting period.

A number of other hedge funds have also added to or reduced their stakes in DRNA. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in shares of Dicerna Pharmaceuticals by 512.2% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,459 shares of the biopharmaceutical company’s stock worth $37,000 after buying an additional 2,894 shares during the last quarter. TD Asset Management Inc. acquired a new stake in shares of Dicerna Pharmaceuticals during the 4th quarter worth approximately $169,000. State Board of Administration of Florida Retirement System increased its holdings in shares of Dicerna Pharmaceuticals by 19.9% during the 4th quarter. State Board of Administration of Florida Retirement System now owns 18,234 shares of the biopharmaceutical company’s stock worth $195,000 after buying an additional 3,024 shares during the last quarter. Virtus ETF Advisers LLC acquired a new stake in shares of Dicerna Pharmaceuticals during the 4th quarter worth approximately $261,000. Finally, Allianz Asset Management GmbH acquired a new stake in shares of Dicerna Pharmaceuticals during the 3rd quarter worth approximately $375,000. Institutional investors own 85.29% of the company’s stock.

NASDAQ:DRNA opened at $14.91 on Friday. The company has a market cap of $1.02 billion, a P/E ratio of -12.43 and a beta of 2.42. Dicerna Pharmaceuticals Inc has a fifty-two week low of $9.31 and a fifty-two week high of $17.98.

Dicerna Pharmaceuticals (NASDAQ:DRNA) last posted its quarterly earnings data on Monday, March 11th. The biopharmaceutical company reported ($0.29) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.23) by ($0.06). The company had revenue of $1.54 million for the quarter, compared to analysts’ expectations of $8.38 million. Dicerna Pharmaceuticals had a negative return on equity of 53.27% and a negative net margin of 1,438.68%. As a group, analysts expect that Dicerna Pharmaceuticals Inc will post -0.99 earnings per share for the current fiscal year.

A number of brokerages have recently issued reports on DRNA. ValuEngine upgraded shares of Dicerna Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Thursday, March 21st. BidaskClub upgraded shares of Dicerna Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Friday, March 22nd. Zacks Investment Research downgraded shares of Dicerna Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, March 14th. SunTrust Banks raised their price target on shares of Dicerna Pharmaceuticals to $26.00 and gave the stock a “buy” rating in a report on Wednesday, March 13th. Finally, B. Riley raised their price target on shares of Dicerna Pharmaceuticals from $21.00 to $24.00 and gave the stock a “buy” rating in a report on Wednesday, March 13th. One investment analyst has rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $21.78.

In related news, insider James B. Weissman sold 15,000 shares of the stock in a transaction that occurred on Tuesday, April 2nd. The shares were sold at an average price of $15.00, for a total transaction of $225,000.00. Following the completion of the transaction, the insider now owns 39,480 shares of the company’s stock, valued at approximately $592,200. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 19.85% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Two Sigma Investments LP Acquires 34,433 Shares of Dicerna Pharmaceuticals Inc (DRNA)” was first published by Highlight Press and is the property of of Highlight Press. If you are viewing this piece of content on another site, it was illegally stolen and reposted in violation of US and international copyright and trademark laws. The original version of this piece of content can be read at https://highlightpress.com/2019/04/05/two-sigma-investments-lp-acquires-34433-shares-of-dicerna-pharmaceuticals-inc-drna.html.

Dicerna Pharmaceuticals Profile

Dicerna Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery and development of ribonucleic acid interference (RNAi)-based pharmaceuticals. The company develops pharmaceuticals using its GalXC RNAi platform for the treatment of diseases involving the liver, including rare diseases, viral infectious diseases, chronic liver diseases, and cardiovascular diseases.

Featured Story: Ex-Dividend

Want to see what other hedge funds are holding DRNA?Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Dicerna Pharmaceuticals Inc (NASDAQ:DRNA).

Institutional Ownership by Quarter for Dicerna Pharmaceuticals (NASDAQ:DRNA)

Receive News & Ratings for Dicerna Pharmaceuticals Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Dicerna Pharmaceuticals and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts

Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) Holdings Raised by BlackRock Inc.

BlackRock Inc. lifted its holdings in Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) by 13.8% during the third quarter, according to its most recent 13F …

Dicerna Pharmaceuticals logoBlackRock Inc. lifted its holdings in Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) by 13.8% during the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 2,967,073 shares of the biopharmaceutical company’s stock after buying an additional 359,178 shares during the period. BlackRock Inc. owned approximately 4.73% of Dicerna Pharmaceuticals worth $45,277,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. Northern Trust Corp lifted its position in shares of Dicerna Pharmaceuticals by 719.5% during the second quarter. Northern Trust Corp now owns 486,668 shares of the biopharmaceutical company’s stock worth $5,962,000 after acquiring an additional 427,284 shares in the last quarter. Emerald Mutual Fund Advisers Trust increased its position in shares of Dicerna Pharmaceuticals by 72.6% during the third quarter. Emerald Mutual Fund Advisers Trust now owns 909,220 shares of the biopharmaceutical company’s stock valued at $13,875,000 after acquiring an additional 382,361 shares in the last quarter. Emerald Advisers Inc. PA grew its position in Dicerna Pharmaceuticals by 61.2% in the 3rd quarter. Emerald Advisers Inc. PA now owns 972,622 shares of the biopharmaceutical company’s stock worth $14,842,000 after purchasing an additional 369,114 shares during the period. Candriam Luxembourg S.C.A. bought a new stake in Dicerna Pharmaceuticals in the 3rd quarter worth approximately $4,448,000. Finally, Bank of New York Mellon Corp grew its position in Dicerna Pharmaceuticals by 288.3% in the 2nd quarter. Bank of New York Mellon Corp now owns 160,898 shares of the biopharmaceutical company’s stock worth $1,971,000 after purchasing an additional 119,466 shares during the period. Hedge funds and other institutional investors own 87.22% of the company’s stock.

Shares of DRNA traded down $0.21 during mid-day trading on Wednesday, hitting $10.16. The company’s stock had a trading volume of 258,610 shares, compared to its average volume of 448,344. Dicerna Pharmaceuticals Inc has a 52-week low of $8.71 and a 52-week high of $17.98. The stock has a market capitalization of $678.13 million, a PE ratio of -2.78 and a beta of 2.23.

Dicerna Pharmaceuticals (NASDAQ:DRNA) last posted its earnings results on Monday, November 5th. The biopharmaceutical company reported ($0.35) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.24) by ($0.11). Dicerna Pharmaceuticals had a negative net margin of 1,418.01% and a negative return on equity of 63.24%. The firm had revenue of $1.55 million for the quarter, compared to analysts’ expectations of $1.67 million. On average, equities analysts expect that Dicerna Pharmaceuticals Inc will post -1.15 earnings per share for the current fiscal year.

Several research analysts have recently weighed in on the stock. Chardan Capital upgraded shares of Dicerna Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $18.00 price target on the stock in a research note on Tuesday, January 22nd. Zacks Investment Research cut shares of Dicerna Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, January 17th. BidaskClub cut shares of Dicerna Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, January 12th. Leerink Swann assumed coverage on shares of Dicerna Pharmaceuticals in a report on Tuesday, November 27th. They issued an “outperform” rating and a $24.00 target price on the stock. Finally, B. Riley upgraded shares of Dicerna Pharmaceuticals from a “neutral” rating to a “buy” rating and boosted their target price for the stock from $13.50 to $21.00 in a report on Tuesday, November 6th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and nine have issued a buy rating to the stock. The company has an average rating of “Buy” and an average price target of $20.78.

ILLEGAL ACTIVITY WARNING: “Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) Holdings Raised by BlackRock Inc.” was published by Fairfield Current and is owned by of Fairfield Current. If you are accessing this piece of content on another domain, it was stolen and reposted in violation of international copyright & trademark laws. The correct version of this piece of content can be accessed at https://www.fairfieldcurrent.com/news/2019/02/06/blackrock-inc-increases-holdings-in-dicerna-pharmaceuticals-inc-drna.html.

Dicerna Pharmaceuticals Company Profile

Dicerna Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery and development of pharmaceuticals for the treatment of rare, viral infectious, chronic liver, and cardiovascular diseases. Its development programs include DCR-PHXC for the treatment of primary hyperoxaluria; DCR-HBVS for the treatment of chronic hepatitis B virus infection; and DCR-PCSK9 to treat hypercholesterolemia.

Read More: Do Tariffs Work?

Institutional Ownership by Quarter for Dicerna Pharmaceuticals (NASDAQ:DRNA)

Receive News & Ratings for Dicerna Pharmaceuticals Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Dicerna Pharmaceuticals and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts

Ecor1 Capital Has Cut Dicerna Pharmaceuticals Ord (DRNA) Holding as Stock Rose; Duke Energy …

Amica Mutual Insurance Company decreased its stake in Duke Energy Corporation (DUK) by 18.02% based on its latest 2018Q1 regulatory filing with …

August 16, 2018 – By Ash Maslow

Duke Energy Corporation (NYSE:DUK) Logo

Ecor1 Capital Llc decreased its stake in Dicerna Pharmaceuticals Ord (DRNA) by 1.49% based on its latest 2018Q1 regulatory filing with the SEC. Ecor1 Capital Llc sold 72,100 shares as the company’s stock rose 0.36% while stock markets declined. The institutional investor held 4.76M shares of the health care company at the end of 2018Q1, valued at $45.55M, down from 4.84M at the end of the previous reported quarter. Ecor1 Capital Llc who had been investing in Dicerna Pharmaceuticals Ord for a number of months, seems to be less bullish one the $769.36 million market cap company. The stock decreased 1.96% or $0.29 during the last trading session, reaching $14.53. About 788,903 shares traded or 62.91% up from the average. Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) has risen 317.27% since August 16, 2017 and is uptrending. It has outperformed by 304.70% the S&P500. Some Historical DRNA News: 20/04/2018 – Biotech companies Alnylam, Dicerna settle trade secrets case; 08/03/2018 Dicerna Pharmaceuticals 4Q Loss/Shr 90c; 09/04/2018 – Dicerna Presenting at Conference Tomorrow; 20/04/2018 – DICERNA PHARMACEUTICALS – SETTLEMENT ALLOWS CO TO ADVANCE ALL KEY, PLANNED PIPELINE PROGRAMS; 20/04/2018 – ADVISORY-Alert on Dicerna, Alnylam litigation settlement wrongly coded to American Lorain; 23/03/2018 – Report: Exploring Fundamental Drivers Behind Goldfield, Dicerna Pharmaceuticals, Deciphera Pharmaceuticals, WesBanco, Carolina; 20/04/2018 – Alnylam Reaches Settlement Agreement with Dicerna Pharmaceuticals Resolving Trade Secret Misappropriation and Other Pending Litigation; 20/04/2018 – DICERNA PHARMACEUTICALS – SETTLEMENT EXCLUDES ANY AMOUNTS RECEIVED BY DICERNA FROM ITS EXISTING COLLABORATION WITH BOEHRINGER-INGELHEIM; 19/04/2018 – DJ Dicerna Pharmaceuticals Inc, Inst Holders, 1Q 2018 (DRNA); 20/04/2018 – Alnylam Reaches Settlement Agreement with Dicerna Pharmaceuticals Resolving Trade Secret Misappropriation and Other Pending

Amica Mutual Insurance Company decreased its stake in Duke Energy Corporation (DUK) by 18.02% based on its latest 2018Q1 regulatory filing with the SEC. Amica Mutual Insurance Company sold 4,962 shares as the company’s stock declined 2.71% with the market. The institutional investor held 22,576 shares of the power generation company at the end of 2018Q1, valued at $1.75M, down from 27,538 at the end of the previous reported quarter. Amica Mutual Insurance Company who had been investing in Duke Energy Corporation for a number of months, seems to be less bullish one the $58.31B market cap company. The stock increased 0.79% or $0.64 during the last trading session, reaching $81.86. About 3.68M shares traded or 5.21% up from the average. Duke Energy Corporation (NYSE:DUK) has declined 10.96% since August 16, 2017 and is downtrending. It has underperformed by 23.53% the S&P500. Some Historical DUK News: 13/03/2018 – Vectren draws three suitors in second round; 15/05/2018 – Duke Energy Picks Sites in Six Indiana Counties to Improve For Potential Industrial Development; 10/05/2018 – Duke Energy 1Q EPS 88c; 15/05/2018 – Duke Energy helps advance site readiness projects in six Indiana counties; 19/03/2018 – Piedmont Natural Gas seeks approval to reduce customer billing rates in North Carolina; 22/03/2018 – Duke Energy: Sees Investing $11B Over 2017-2026 in New Natural Gas-Fired, Wind and Solar Generation; 25/04/2018 – Duke Energy Names Harry Sideris Chief Distribution Officer; 05/03/2018 DUKE ENERGY CORP DUK.N : UBS RAISES TARGET PRICE TO $87 FROM $86; 30/04/2018 – DUKE: RENEWABLE ENERGY PORTFOLIO GREW ALMOST 20% IN 2017; 10/05/2018 – Duke Energy 1Q Adj EPS $1.28

Among 9 analysts covering Dicerna Pharmaceuticals (NASDAQ:DRNA), 4 have Buy rating, 0 Sell and 5 Hold. Therefore 44% are positive. Dicerna Pharmaceuticals had 26 analyst reports since August 7, 2015 according to SRatingsIntel. The rating was maintained by Chardan Capital Markets with “Hold” on Friday, August 11. Stifel Nicolaus maintained it with “Buy” rating and $16 target in Tuesday, May 10 report. The stock of Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) has “Outperform” rating given on Tuesday, September 8 by Cowen & Co. H.C. Wainwright initiated Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) rating on Monday, December 12. H.C. Wainwright has “Buy” rating and $7 target. The firm has “Neutral” rating given on Friday, March 23 by H.C. Wainwright. The stock has “Neutral” rating by Chardan Capital Markets on Monday, August 15. The stock of Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) earned “Buy” rating by Stifel Nicolaus on Thursday, June 30. The rating was maintained by Chardan Capital Markets with “Neutral” on Thursday, June 30. Cowen & Co maintained the stock with “Buy” rating in Wednesday, August 16 report. Stifel Nicolaus maintained Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) rating on Thursday, August 9. Stifel Nicolaus has “Buy” rating and $20 target.

Ecor1 Capital Llc, which manages about $997.01M US Long portfolio, upped its stake in Array Biopharma Inc (NASDAQ:ARRY) by 166,600 shares to 3.05M shares, valued at $49.77 million in 2018Q1, according to the filing. It also increased its holding in Fibrogen Inc (Call) by 39,600 shares in the quarter, for a total of 325,000 shares, and has risen its stake in Immune Design Corp (NASDAQ:IMDZ).

More notable recent Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) news were published by: Streetinsider.com which released: “HC Wainwright Upgrades Dicerna Pharmaceuticals (DRNA) to Buy” on August 15, 2018, also Seekingalpha.com with their article: “Premarket analyst action – healthcare” published on August 15, 2018, Benzinga.com published: “Benzinga’s Top Upgrades, Downgrades For August 15, 2018” on August 15, 2018. More interesting news about Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) were released by: Benzinga.com and their article: “Earnings Outlook For Dicerna Pharmaceuticals” published on August 08, 2018 as well as Businesswire.com‘s news article titled: “Dicerna Reports Second Quarter 2018 Financial and Operating Results and Provides Corporate Update” with publication date: August 08, 2018.

Analysts await Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) to report earnings on November, 1. They expect $-0.25 earnings per share, up 72.83% or $0.67 from last year’s $-0.92 per share. After $-0.28 actual earnings per share reported by Dicerna Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -10.71% EPS growth.

Investors sentiment decreased to 2.44 in Q1 2018. Its down 0.56, from 3 in 2017Q4. It turned negative, as 3 investors sold DRNA shares while 13 reduced holdings. 24 funds opened positions while 15 raised stakes. 30.68 million shares or 5.45% more from 29.10 million shares in 2017Q4 were reported. 32 are held by Bnp Paribas Arbitrage. 683 Capital Management Limited Company has invested 0.11% in Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA). Citadel Advisors Ltd holds 170,741 shares. The Vermont-based Birchview Lp has invested 0.28% in Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA). Caxton Corporation owns 13,074 shares for 0.15% of their portfolio. Fmr Limited Liability reported 1.71M shares. California Pub Employees Retirement Sys holds 41,000 shares. Quantitative Systematic Strategies Ltd Liability Corporation accumulated 0.02% or 11,794 shares. Element Cap Mgmt Ltd Com owns 0.02% invested in Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) for 82,957 shares. 22,583 are held by State Street. Geode Cap Mgmt Ltd Liability Co holds 161,577 shares. Laurion Mgmt Lp has invested 0% in Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA). Goldman Sachs Group holds 0% in Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) or 788,604 shares. 4.76M are held by Ecor1 Capital Ltd Company. Tiff Advisory, a Pennsylvania-based fund reported 29,714 shares.

Since March 19, 2018, it had 0 insider buys, and 4 selling transactions for $425,035 activity. $145,035 worth of Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) was sold by Brown Bob D.

Analysts await Duke Energy Corporation (NYSE:DUK) to report earnings on November, 2. They expect $1.54 EPS, down 3.14% or $0.05 from last year’s $1.59 per share. DUK’s profit will be $1.10 billion for 13.29 P/E if the $1.54 EPS becomes a reality. After $0.93 actual EPS reported by Duke Energy Corporation for the previous quarter, Wall Street now forecasts 65.59% EPS growth.

Among 20 analysts covering Duke Energy (NYSE:DUK), 7 have Buy rating, 2 Sell and 11 Hold. Therefore 35% are positive. Duke Energy had 97 analyst reports since August 7, 2015 according to SRatingsIntel. As per Thursday, October 12, the company rating was maintained by JP Morgan. The stock of Duke Energy Corporation (NYSE:DUK) earned “Hold” rating by SunTrust on Monday, December 11. The stock of Duke Energy Corporation (NYSE:DUK) earned “Hold” rating by SunTrust on Sunday, January 28. SunTrust maintained the stock with “Hold” rating in Monday, April 16 report. As per Friday, January 8, the company rating was maintained by Argus Research. The stock has “Hold” rating by SunTrust on Monday, February 5. The company was maintained on Tuesday, July 24 by Howard Weil. Argus Research maintained it with “Buy” rating and $79 target in Tuesday, September 15 report. RBC Capital Markets maintained the shares of DUK in report on Sunday, August 27 with “Buy” rating. SunTrust maintained Duke Energy Corporation (NYSE:DUK) on Tuesday, December 26 with “Hold” rating.

Investors sentiment decreased to 0.9 in 2018 Q1. Its down 0.23, from 1.13 in 2017Q4. It dived, as 73 investors sold DUK shares while 401 reduced holdings. 107 funds opened positions while 319 raised stakes. 402.81 million shares or 3.36% more from 389.71 million shares in 2017Q4 were reported. Klingenstein Fields And Ltd Liability Corporation holds 0.01% or 3,713 shares in its portfolio. Bridgeway Capital Management has 0.62% invested in Duke Energy Corporation (NYSE:DUK). Guardian Capital Advsr LP reported 101,718 shares. Moreover, Bridges Inv Mngmt has 0.01% invested in Duke Energy Corporation (NYSE:DUK). S R Schill has invested 0.38% of its portfolio in Duke Energy Corporation (NYSE:DUK). State Board Of Administration Of Florida Retirement accumulated 964,641 shares or 0.2% of the stock. Catawba Management Va holds 57,435 shares. 105 are held by Psagot House. Cadence Mngmt Limited Liability Corporation accumulated 42,543 shares or 0.21% of the stock. 10 are owned by Mitsubishi Ufj Hldgs Limited. Royal Financial Bank Of Canada has 0.2% invested in Duke Energy Corporation (NYSE:DUK). Blb&B Advisors Ltd Llc accumulated 54,785 shares. Waddell & Reed Financial holds 0.03% of its portfolio in Duke Energy Corporation (NYSE:DUK) for 150,000 shares. Carroll accumulated 145,743 shares. Pennsylvania-based Biondo Inv Advsrs Llc has invested 0.85% in Duke Energy Corporation (NYSE:DUK).

Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) Institutional Positions Chart

Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.

Related Posts:

  • No Related Posts

Dicerna Pharmaceuticals Inc (DRNA) Stake Increased by Millennium Management LLC

Millennium Management LLC increased its position in shares of Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) by 142.8% in the 4th quarter, …

Dicerna Pharmaceuticals logoMillennium Management LLC increased its position in shares of Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) by 142.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 66,907 shares of the biopharmaceutical company’s stock after purchasing an additional 39,348 shares during the quarter. Millennium Management LLC owned 0.13% of Dicerna Pharmaceuticals worth $604,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of DRNA. Emerald Advisers Inc. PA bought a new position in shares of Dicerna Pharmaceuticals in the fourth quarter worth about $266,000. EAM Investors LLC bought a new position in shares of Dicerna Pharmaceuticals in the fourth quarter worth about $581,000. Deutsche Bank AG lifted its holdings in shares of Dicerna Pharmaceuticals by 225.8% in the fourth quarter. Deutsche Bank AG now owns 168,400 shares of the biopharmaceutical company’s stock worth $1,520,000 after acquiring an additional 116,719 shares during the last quarter. Goldman Sachs Group Inc. lifted its holdings in shares of Dicerna Pharmaceuticals by 84.2% in the fourth quarter. Goldman Sachs Group Inc. now owns 194,198 shares of the biopharmaceutical company’s stock worth $1,754,000 after acquiring an additional 88,778 shares during the last quarter. Finally, Monashee Investment Management LLC bought a new position in shares of Dicerna Pharmaceuticals in the fourth quarter worth about $1,878,000. 77.28% of the stock is owned by institutional investors and hedge funds.

DRNA has been the subject of a number of research reports. Evercore ISI reissued an “outperform” rating and issued a $17.00 target price (up previously from $14.00) on shares of Dicerna Pharmaceuticals in a report on Friday, April 20th. BidaskClub lowered shares of Dicerna Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Wednesday, March 21st. HC Wainwright lowered shares of Dicerna Pharmaceuticals from a “buy” rating to a “neutral” rating and set a $12.00 price objective for the company. in a report on Friday, March 23rd. B. Riley assumed coverage on shares of Dicerna Pharmaceuticals in a report on Wednesday, March 28th. They issued a “neutral” rating and a $10.00 price objective for the company. Finally, Zacks Investment Research lowered shares of Dicerna Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, February 9th. One research analyst has rated the stock with a sell rating, three have issued a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average price target of $12.88.

In other Dicerna Pharmaceuticals news, insider James B. Weissman sold 8,965 shares of the stock in a transaction that occurred on Friday, April 20th. The shares were sold at an average price of $13.00, for a total transaction of $116,545.00. Following the completion of the sale, the insider now owns 9,800 shares of the company’s stock, valued at approximately $127,400. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider James B. Weissman sold 10,000 shares of the stock in a transaction that occurred on Wednesday, May 9th. The shares were sold at an average price of $15.00, for a total transaction of $150,000.00. Following the sale, the insider now directly owns 19,800 shares of the company’s stock, valued at approximately $297,000. The disclosure for this sale can be found here. Insiders have sold a total of 20,000 shares of company stock valued at $280,000 in the last three months. Insiders own 19.85% of the company’s stock.

NASDAQ DRNA traded down $0.09 during trading hours on Tuesday, reaching $14.56. The company’s stock had a trading volume of 264,906 shares, compared to its average volume of 409,496. The firm has a market cap of $761.16 million, a PE ratio of -3.98 and a beta of 2.34. Dicerna Pharmaceuticals Inc has a 52 week low of $2.69 and a 52 week high of $15.80.

Dicerna Pharmaceuticals (NASDAQ:DRNA) last released its earnings results on Monday, May 14th. The biopharmaceutical company reported ($0.30) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.87) by $0.57. The business had revenue of $1.55 million during the quarter, compared to the consensus estimate of $1.75 million. Dicerna Pharmaceuticals had a negative net margin of 1,665.11% and a negative return on equity of 123.72%. analysts predict that Dicerna Pharmaceuticals Inc will post -1.35 EPS for the current year.

About Dicerna Pharmaceuticals

Dicerna Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery and development of pharmaceuticals for the treatment of rare, viral infectious, chronic liver, and cardiovascular diseases. Its development programs include DCR-PHXC for the treatment of primary hyperoxaluria; DCR-HBVS for the treatment of chronic hepatitis B virus infection; and DCR-PCSK9 to treat hypercholesterolemia.

Institutional Ownership by Quarter for Dicerna Pharmaceuticals (NASDAQ:DRNA)

Receive News & Ratings for Dicerna Pharmaceuticals Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Dicerna Pharmaceuticals and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts